ClinicalTrials.gg
CompletedNCT03793608Updated May 19, 2022Results posted

Study to Evaluate Dupilumab Monotherapy in Pediatric Patients With Peanut Allergy

A Phase 2 interventional study of Dupilumab in Peanut Allergy, sponsored by Regeneron Pharmaceuticals. Completed at 9 sites in 2 countries. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2022-05-19.

Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
6 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 99 studies in Peanut Hypersensitivity with a site in United States — 10 open to participants now, 16 under way, 3 of them phase 3. Peanut Hypersensitivity · United States.

Enrollment
61st of 87
25 · median 47
Started
2019
with 5 others
Phase 2
26 of 99
3 open now
Registered
63rd of 99
by date

Among the 99 studies in Peanut Hypersensitivity with a site in United States, this one is the 61st largest by enrollment of the 87 interventional ones that give a count, is one of 6 that started in 2019, is one of 26 in phase 2, and was the 63rd registered.

Peanut Hypersensitivity

166 studies on the registry are indexed under Peanut Hypersensitivity; 27 are open to participants now.

Browse Peanut Hypersensitivity studies →

Open to participants now

10 of the 99 studies in Peanut Hypersensitivity with a site in United States are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 18 Peanut Hypersensitivity studies recruiting now, 2 (11%) set no upper age limit and 16 (89%) stop at 75 or younger; 15 take children under 18; 6 take healthy volunteers.

This study: 6 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 99 studies in Peanut Hypersensitivity with a site in United States, or all of them as a file.
02

Study summary

The primary objective of the study is to assess the tolerability of peanut protein in pediatric patients (6-17 years old) treated with dupilumab monotherapy, in which tolerability is defined as the proportion of patients who safely pass a double-blind placebo-controlled food challenge (DBPCFC) at week 24.

The secondary objectives are:

  • To determine whether dupilumab treatment improves peanut tolerability, defined as a change in the cumulative tolerated dose (log transformed) of peanut protein during a DBPCFC
  • To evaluate the safety and tolerability of dupilumab treatment in peanut allergic patients
  • To evaluate the effects of dupilumab treatment on the levels of peanut-specific Immunoglobulin E (IgE)
  • To evaluate the treatment effect of dupilumab on the average wheal size after a titrated skin prick test (SPT), as measured by area under curve (AUC) of the average wheal size induced by peanut extract at different concentrations
  • To assess the incidence of treatment-emergent anti-drug antibodies (ADA) to dupilumab in patients over time
03

Conditions studied

  • Peanut Allergy
04

Who can participate

Ages eligible
6 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Patient has a clinical history of allergy to peanuts or peanut-containing foods (symptom[s] of reaction due to exposure).
  • Experience dose-limiting symptoms at or before the challenge dose of peanut protein on screening DBPCFC conducted in accordance with Practical Issues in Allergology, Joint United States/European Union Initiative (PRACTALL) guidelines. And not experiencing dose limiting symptoms to placebo
  • Serum IgE to peanut of ≥10 kilo units (kUA)/L and/or a SPT to peanut ≥8 mm compared to a negative control
  • Patients/legal guardians must be trained on the proper use of the epinephrine autoinjector device to be allowed to enroll in the study
  • Patients with other known food allergies must agree to eliminate these other food items from their diet so as not to confound the safety and efficacy data from the study

Key Exclusion Criteria:

  • Any previous exposure to marketed dupilumab or dupilumab in a clinical trial
  • Member of the clinical site study team or his/her immediate family
  • History of other chronic disease (other than asthma, AD, or allergic rhinitis) requiring therapy
  • History of frequent or recent severe, life-threatening episode of anaphylaxis or anaphylactic shock as defined by more than 3 episodes of anaphylaxis within the past year and/or an episode of anaphylaxis within 60 days of screening DBPCFC
  • History of eosinophilic gastrointestinal disease
  • History of eosinophilic granulomatosis with polyangiitis
  • Severe, unstable asthma at time of enrollment or any patient with (FEV1) \<80% of predicted or asthma control questionnaire (ACQ)>1.5
  • Use of systemic within 2 months prior to screening

Note: Other protocol Inclusion/Exclusion Criteria apply

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    Dupilumab

    Open label weight base subcutaneous (SC) injection every two (Q2) weeks.

    Drug: Dupilumab

Interventions

  • Dupilumab weight-based dosing will be administered subcutaneously (SC) in a single-use, pre-filled syringe every two weeks (Q2W)

    Also known as: REGN668, IL4R, Dupixent, SAR231893

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Treated With Dupilumab Who Passed a DBPCFC With at Least 444 mg (Cumulative) Peanut Protein at Week 24

    Symptoms considered to be allergic were graded using the Consortium of Food Allergy Research (CoFAR) Grading Scale for Systemic Allergic Reactions. The scale is Grade 1 (Mild) through 5, the higher the grade, the more severe the allergic reaction. Participants were considered to have passed the DBPCFC if they did not experience any objective Grade 1 reaction. Percentage of participants treated with dupilumab who passed the DBPCFC with at least 444 mg (cumulative) peanut protein at Week 24 was reported.

    Time frame: At Week 24

Secondary outcomes

  1. Change From Baseline in Cumulative Tolerated Dose (Log Transformed) of Peanut Protein During a DBPCFC at Weeks 24 and 36

    Change from baseline in cumulative tolerated dose (log transformed) of peanut protein during a DBPCFC at Week 24 and Week 36 was reported.

    Time frame: Weeks 24 and 36

  2. Percentage of Participants Treated With Dupilumab Who Passed a DBPCFC With at Least 444 mg (Cumulative) Peanut Protein at Week 36

    Symptoms considered to be allergic were graded using the Consortium of Food Allergy Research (CoFAR) Grading Scale for Systemic Allergic Reactions. The scale is Grade 1 (Mild) through 5, the higher the grade, the more severe the allergic reaction. Participants were considered to have passed the DBPCFC if they did not experience any objective Grade 1 reaction. Only participants treated with dupilumab who passed at least 444 mg (cumulative) peanut challenge at Week 24 were eligible for Week 36 DBFC.

    Time frame: At Week 36

  3. Percentage of Participants Treated With Dupilumab Who Passed a DBPCFC With at Least 1044 mg (Cumulative) Peanut Protein at Week 24

    Symptoms considered to be allergic were graded using the Consortium of Food Allergy Research (CoFAR) Grading Scale for Systemic Allergic Reactions. The scale is Grade 1 (Mild) through 5, the higher the grade, the more severe the allergic reaction. Participants were considered to have passed the DBPCFC if they did not experience any objective Grade 1 reaction. Percentage of participants treated with dupilumab who passed a DBPCFC with at least 1044 mg (cumulative) peanut protein at Week 24 was reported.

    Time frame: At Week 24

  4. Percentage of Participants Treated With Dupilumab Who Passed a DBPCFC With at Least 1044 mg (Cumulative) Peanut Protein at Week 36

    Symptoms considered to be allergic were graded using the Consortium of Food Allergy Research (CoFAR) Grading Scale for Systemic Allergic Reactions. The scale is Grade 1 (Mild) through 5, the higher the grade, the more severe the allergic reaction. Participants were considered to have passed the DBPCFC if they did not experience any objective Grade 1 reaction. Only participants treated with dupilumab who passed at least 444 mg (cumulative) peanut challenge at Week 24 were eligible for Week 36 DBFC.

    Time frame: At Week 36

  5. Percentage of Participants Treated With Dupilumab Who Passed a DBPCFC With at Least 2044 mg (Cumulative) Peanut Protein at Week 24

    Symptoms considered to be allergic were graded using the Consortium of Food Allergy Research (CoFAR) Grading Scale for Systemic Allergic Reactions. The scale is Grade 1 (Mild) through 5, the higher the grade, the more severe the allergic reaction. Participants were considered to have passed the DBPCFC if they did not experience any objective Grade 1 reaction. Percentage of participants treated with dupilumab who passed a DBPCFC with at least 2044 mg (cumulative) peanut protein at Week 24 was reported.

    Time frame: At Week 24

  6. Percentage of Participants Treated With Dupilumab Who Passed a DBPCFC With at Least 2044 mg (Cumulative) Peanut Protein at Week 36

    Symptoms considered to be allergic were graded using the Consortium of Food Allergy Research (CoFAR) Grading Scale for Systemic Allergic Reactions. The scale is Grade 1 (Mild) through 5, the higher the grade, the more severe the allergic reaction. Participants were considered to have passed the DBPCFC if they did not experience any objective Grade 1 reaction. Only participants treated with dupilumab who passed at least 444 mg (cumulative) peanut challenge at Week 24 were eligible for Week 36 DBFC.

    Time frame: At Week 36

  7. Percent Change From Baseline in Peanut-specific Immunoglobulin E (sIgE) at Weeks 4, 8, 12, 16, 24, and 36

    Percent change from baseline in sIgE at Weeks 4, 8, 12, 16, 24, and 36 was reported.

    Time frame: Weeks 4, 8, 12, 16, 24, and 36

  8. Change From Baseline in Titrated Skin Prick Test (SPT) Measured by Average Wheal Size Area Under the Curve (AUC) After Peanut Allergen Stimulation at Different Concentrations at Weeks 4, 12, 24, and 36

    The titrated SPT is the skin testing for atopic response at different concentrations of peanut extract with saline as negative control and histamine as positive controls. Wheal size induced by peanut extract at each concentration was calculated as average of largest diameter and perpendicular midpoint diameter. The AUC for titrated SPT was calculated using the mean wheal diameter versus the concentration at which the wheal diameter was measured, which was then normalized to concentration. Change from baseline in titrated SPT as measured by average wheal size AUC after peanut allergen stimulation at different concentrations at Weeks 4, 12, 24, and 36 was reported.

    Time frame: Weeks 4, 12, 24, and 36

  9. Percentage of Participants With Grade 2 or Above Allergic Reactions During the DBPCFC at Week 24

    Symptoms considered to be allergic were graded using the Consortium of Food Allergy Research (CoFAR) Grading Scale for Systemic Allergic Reactions. The scale is Grade 1 (Mild) through 5, the higher the grade, the more severe the allergic reaction. Percentage of participants with Grade 2 (Moderate) or above allergic reactions during the DBPCFC at Week 24 was reported.

    Time frame: At Week 24

  10. Percentage of Participants Who Used Epinephrine as a Rescue Medication During the DBPCFC at Week 24

    Percentage of participants who used Epinephrine as a rescue medication during the DBPCFC at Week 24 was reported.

    Time frame: At Week 24

07

Results

Posted May 19, 2022

Participant flow

Twenty-five participants met eligibility criteria. One of the 25 participants was randomized under the original double-blind placebo-controlled protocol and received placebo-matching dupilumab. Following implementation of Protocol Amendment 1, 24 participants were enrolled under the open-label design \& received open-label treatment with dupilumab.

Participant flow — Overall Study
MilestonePlaceboDupilumab
Started124
Treated124
Safety analysis set (saf)024
Completed124
Not completed00

Outcome measures

PrimaryPercentage of Participants Treated With Dupilumab Who Passed a DBPCFC With at Least 444 mg (Cumulative) Peanut Protein at Week 24

Symptoms considered to be allergic were graded using the Consortium of Food Allergy Research (CoFAR) Grading Scale for Systemic Allergic Reactions. The scale is Grade 1 (Mild) through 5, the higher the grade, the more severe the allergic reaction. Participants were considered to have passed the DBPCFC if they did not experience any objective Grade 1 reaction. Percentage of participants treated with dupilumab who passed the DBPCFC with at least 444 mg (cumulative) peanut protein at Week 24 was reported.

Time frame:
At Week 24
Reported as:
Number · Percentage of Participants
Percentage of Participants Treated With Dupilumab Who Passed a DBPCFC With at Least 444 mg (Cumulative) Peanut Protein at Week 24
Percentage of ParticipantsDupilumab
Percentage of Participants Treated With Dupilumab Who Passed a DBPCFC With at Least 444 mg (Cumulative) Peanut Protein at Week 248.3 (1.03 to 27.00)
SecondaryChange From Baseline in Cumulative Tolerated Dose (Log Transformed) of Peanut Protein During a DBPCFC at Weeks 24 and 36

Change from baseline in cumulative tolerated dose (log transformed) of peanut protein during a DBPCFC at Week 24 and Week 36 was reported.

Time frame:
Weeks 24 and 36
Reported as:
Mean · Log Transformed Milligrams
Change From Baseline in Cumulative Tolerated Dose (Log Transformed) of Peanut Protein During a DBPCFC at Weeks 24 and 36
Log Transformed MilligramsDupilumab
Change at Week 240.69 ± 1.822
Change at Week 363.38 ± 3.096
SecondaryPercentage of Participants Treated With Dupilumab Who Passed a DBPCFC With at Least 444 mg (Cumulative) Peanut Protein at Week 36

Symptoms considered to be allergic were graded using the Consortium of Food Allergy Research (CoFAR) Grading Scale for Systemic Allergic Reactions. The scale is Grade 1 (Mild) through 5, the higher the grade, the more severe the allergic reaction. Participants were considered to have passed the DBPCFC if they did not experience any objective Grade 1 reaction. Only participants treated with dupilumab who passed at least 444 mg (cumulative) peanut challenge at Week 24 were eligible for Week 36 DBFC.

Time frame:
At Week 36
Reported as:
Number · Percentage of Participants
Percentage of Participants Treated With Dupilumab Who Passed a DBPCFC With at Least 444 mg (Cumulative) Peanut Protein at Week 36
Percentage of ParticipantsDupilumab
Percentage of Participants Treated With Dupilumab Who Passed a DBPCFC With at Least 444 mg (Cumulative) Peanut Protein at Week 3650.0
SecondaryPercentage of Participants Treated With Dupilumab Who Passed a DBPCFC With at Least 1044 mg (Cumulative) Peanut Protein at Week 24

Symptoms considered to be allergic were graded using the Consortium of Food Allergy Research (CoFAR) Grading Scale for Systemic Allergic Reactions. The scale is Grade 1 (Mild) through 5, the higher the grade, the more severe the allergic reaction. Participants were considered to have passed the DBPCFC if they did not experience any objective Grade 1 reaction. Percentage of participants treated with dupilumab who passed a DBPCFC with at least 1044 mg (cumulative) peanut protein at Week 24 was reported.

Time frame:
At Week 24
Reported as:
Number · Percentage of Participants
Percentage of Participants Treated With Dupilumab Who Passed a DBPCFC With at Least 1044 mg (Cumulative) Peanut Protein at Week 24
Percentage of ParticipantsDupilumab
Percentage of Participants Treated With Dupilumab Who Passed a DBPCFC With at Least 1044 mg (Cumulative) Peanut Protein at Week 240.0 (0.00 to 14.25)
SecondaryPercentage of Participants Treated With Dupilumab Who Passed a DBPCFC With at Least 1044 mg (Cumulative) Peanut Protein at Week 36

Symptoms considered to be allergic were graded using the Consortium of Food Allergy Research (CoFAR) Grading Scale for Systemic Allergic Reactions. The scale is Grade 1 (Mild) through 5, the higher the grade, the more severe the allergic reaction. Participants were considered to have passed the DBPCFC if they did not experience any objective Grade 1 reaction. Only participants treated with dupilumab who passed at least 444 mg (cumulative) peanut challenge at Week 24 were eligible for Week 36 DBFC.

Time frame:
At Week 36
Reported as:
Number · Percentage of Participants
Percentage of Participants Treated With Dupilumab Who Passed a DBPCFC With at Least 1044 mg (Cumulative) Peanut Protein at Week 36
Percentage of ParticipantsDupilumab
Percentage of Participants Treated With Dupilumab Who Passed a DBPCFC With at Least 1044 mg (Cumulative) Peanut Protein at Week 3650.0
SecondaryPercentage of Participants Treated With Dupilumab Who Passed a DBPCFC With at Least 2044 mg (Cumulative) Peanut Protein at Week 24

Symptoms considered to be allergic were graded using the Consortium of Food Allergy Research (CoFAR) Grading Scale for Systemic Allergic Reactions. The scale is Grade 1 (Mild) through 5, the higher the grade, the more severe the allergic reaction. Participants were considered to have passed the DBPCFC if they did not experience any objective Grade 1 reaction. Percentage of participants treated with dupilumab who passed a DBPCFC with at least 2044 mg (cumulative) peanut protein at Week 24 was reported.

Time frame:
At Week 24
Reported as:
Number · Percentage of Participants
Percentage of Participants Treated With Dupilumab Who Passed a DBPCFC With at Least 2044 mg (Cumulative) Peanut Protein at Week 24
Percentage of ParticipantsDupilumab
Percentage of Participants Treated With Dupilumab Who Passed a DBPCFC With at Least 2044 mg (Cumulative) Peanut Protein at Week 240.0 (0.00 to 14.25)
SecondaryPercentage of Participants Treated With Dupilumab Who Passed a DBPCFC With at Least 2044 mg (Cumulative) Peanut Protein at Week 36

Symptoms considered to be allergic were graded using the Consortium of Food Allergy Research (CoFAR) Grading Scale for Systemic Allergic Reactions. The scale is Grade 1 (Mild) through 5, the higher the grade, the more severe the allergic reaction. Participants were considered to have passed the DBPCFC if they did not experience any objective Grade 1 reaction. Only participants treated with dupilumab who passed at least 444 mg (cumulative) peanut challenge at Week 24 were eligible for Week 36 DBFC.

Time frame:
At Week 36
Reported as:
Number · Percentage of Participants
Percentage of Participants Treated With Dupilumab Who Passed a DBPCFC With at Least 2044 mg (Cumulative) Peanut Protein at Week 36
Percentage of ParticipantsDupilumab
Percentage of Participants Treated With Dupilumab Who Passed a DBPCFC With at Least 2044 mg (Cumulative) Peanut Protein at Week 360.0
SecondaryPercent Change From Baseline in Peanut-specific Immunoglobulin E (sIgE) at Weeks 4, 8, 12, 16, 24, and 36

Percent change from baseline in sIgE at Weeks 4, 8, 12, 16, 24, and 36 was reported.

Time frame:
Weeks 4, 8, 12, 16, 24, and 36
Reported as:
Median · Percent Change
Percent Change From Baseline in Peanut-specific Immunoglobulin E (sIgE) at Weeks 4, 8, 12, 16, 24, and 36
Percent ChangeDupilumab
Percent change at Week 4-7.86 (-19.75 to -1.62)
Percent change at Week 8-21.03 (-33.45 to -10.37)
Percent change at Week 12-32.10 (-40.92 to -11.14)
Percent change at Week 16-32.22 (-47.75 to -16.17)
Percent change at Week 24-49.25 (-61.22 to -31.85)
Percent change at Week 36-58.43 (-71.25 to -45.17)
SecondaryChange From Baseline in Titrated Skin Prick Test (SPT) Measured by Average Wheal Size Area Under the Curve (AUC) After Peanut Allergen Stimulation at Different Concentrations at Weeks 4, 12, 24, and 36

The titrated SPT is the skin testing for atopic response at different concentrations of peanut extract with saline as negative control and histamine as positive controls. Wheal size induced by peanut extract at each concentration was calculated as average of largest diameter and perpendicular midpoint diameter. The AUC for titrated SPT was calculated using the mean wheal diameter versus the concentration at which the wheal diameter was measured, which was then normalized to concentration. Change from baseline in titrated SPT as measured by average wheal size AUC after peanut allergen stimulation at different concentrations at Weeks 4, 12, 24, and 36 was reported.

Time frame:
Weeks 4, 12, 24, and 36
Reported as:
Mean · millimeter (mm)
Change From Baseline in Titrated Skin Prick Test (SPT) Measured by Average Wheal Size Area Under the Curve (AUC) After Peanut Allergen Stimulation at Different Concentrations at Weeks 4, 12, 24, and 36
millimeter (mm)Dupilumab
Change at Week 4-0.633 ± 2.0604
Change at Week 12-0.174 ± 2.0618
Change at Week 24-0.232 ± 2.0610
Change at Week 36-0.364 ± 2.1419
SecondaryPercentage of Participants With Grade 2 or Above Allergic Reactions During the DBPCFC at Week 24

Symptoms considered to be allergic were graded using the Consortium of Food Allergy Research (CoFAR) Grading Scale for Systemic Allergic Reactions. The scale is Grade 1 (Mild) through 5, the higher the grade, the more severe the allergic reaction. Percentage of participants with Grade 2 (Moderate) or above allergic reactions during the DBPCFC at Week 24 was reported.

Time frame:
At Week 24
Reported as:
Number · Percentage of Participants
Percentage of Participants With Grade 2 or Above Allergic Reactions During the DBPCFC at Week 24
Percentage of ParticipantsDupilumab
Percentage of Participants With Grade 2 or Above Allergic Reactions During the DBPCFC at Week 2433.3
SecondaryPercentage of Participants Who Used Epinephrine as a Rescue Medication During the DBPCFC at Week 24

Percentage of participants who used Epinephrine as a rescue medication during the DBPCFC at Week 24 was reported.

Time frame:
At Week 24
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Used Epinephrine as a Rescue Medication During the DBPCFC at Week 24
Percentage of ParticipantsDupilumab
Percentage of Participants Who Used Epinephrine as a Rescue Medication During the DBPCFC at Week 2441.7

Adverse events

Collected over Up to the end of study (Week 36). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/1 (0%)0/1 (0%)0/1 (0%)
Dupilumab0/24 (0%)0/24 (0%)11/24 (45.8%)
Most frequent other events
Showing 10 of 11
Most frequent other events
EventPlaceboDupilumab
Injection site painGeneral disorders0/13/24
Injection site urticariaGeneral disorders0/13/24
HeadacheNervous system disorders0/13/24
Injection site erythemaGeneral disorders0/12/24
Injection site haemorrhageGeneral disorders0/12/24
Injection site reactionGeneral disorders0/12/24
Medical device painGeneral disorders0/12/24
Upper respiratory tract infectionInfections and infestations0/12/24
ContusionInjury, poisoning and procedural complications0/12/24
Pain in extremityMusculoskeletal and connective tissue disorders0/12/24

Baseline characteristics

SAF(all participants who received dupilumab)

Age, Continuous
Age, Continuous(Years)Dupilumab
Mean11.7 ± 3.28
Sex: Female, Male
Sex: Female, Male(Participants)Dupilumab
Female6
Male18
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Dupilumab
Hispanic or Latino2
Not Hispanic or Latino22
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Dupilumab
American Indian or Alaska Native0
Asian3
Native Hawaiian or Other Pacific Islander0
Black or African American1
White19
More than one race0
Unknown or Not Reported1
08

Study locations

9 sites
  • Regeneron Investigational Site
    Mountain View, California 94305, United States
  • Regeneron Investigational Site
    Tampa, Florida 33612, United States
  • Regeneron Investigational Site
    Indianapolis, Indiana 46202, United States
  • Regeneron Investigational Site
    Ypsilanti, Michigan 48197, United States
  • Regeneron Investigational Site
    Bronx, New York 10461, United States
  • Regeneron Investigational Site
    Great Neck, New York 11021, United States
  • Regeneron Investigational Site
    Hamilton, Ontario L8S 1G5, Canada
  • Regeneron Investigational Site
    Toronto, Ontario M5G 1X8, Canada
  • Regeneron Investigational Site
    Montreal, Quebec H3T 1C5, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — All IPD that underlie results in a publication

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: Individual de-identified participant data will be made available once the indication has been approved by a regulatory body, if there is participant consent and there is not a reasonable likelihood of participant re-identification.

Access criteria: Qualified researchers may request access to study documents (including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan) that support the methods and findings reported in a manuscript. Individual de-identified participant data will be made available once the indication has been approved by a regulatory body, if there is participant consent and there is not a reasonable likelihood of participant re-identification.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2019 to primary completion in Feb 2021, 23 months.

Results were first posted in May 2022, 1 year 3 months after primary completion.

Of 18 phase 2 interventional studies under Peanut Hypersensitivity, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 58. This study's 23 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 2, 2019
First posted
Jan 4, 2019
StartActual
Mar 12, 2019
Primary completionActual
Feb 19, 2021
CompletionActual
May 12, 2021
Results first posted
May 19, 2022
Last update
May 19, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 19, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03793608
Collaborators
Sanofi
Responsible party
Sponsor
First posted
Jan 4, 2019
Start date
Mar 12, 2019
Primary completion
Feb 19, 2021
Completion
May 12, 2021
Results posted
May 19, 2022
Last update
May 19, 2022

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dupilumab

Start the discussion